Welcome to Markets Desk, your midday read on the stories moving the needle.
Elon Musk is taking direct aim at Indian billionaire Mukesh Ambani, claiming Starlink has spent five years satisfying every regulatory requirement India demands, yet still cannot get a launch approved. Musk's public challenge raises serious questions about market access, regulatory capture, and whether Reliance's telecom dominance is the real obstacle.
Shifting to pharma, Lupin Limited has secured FDA approval for its Phytonadione Injectable Emulsion, a vitamin K prefilled syringe product expanding the Indian generic manufacturer's foothold in the competitive U S injectable medicines market. It is a incremental but meaningful pipeline win as Lupin continues building its American specialty portfolio.
And on Nvidia, analysts are pushing back on the stock split narrative, arguing that NVDA's real investment case rests entirely on its dominance in AI accelerator chips, data center infrastructure, and software ecosystems — not its share price optics. A split would be cosmetic. The underlying earnings story is what institutional money is watching.
That's the tape. Markets Desk, signing off the floor.
